10-Q: Serina Therapeutics Faces Clinical Hold, Raises Going Concern Doubt

Serina Therapeutics reported increased losses and a clinical hold on its lead Parkinson's drug, raising substantial doubt about its ability to continue as a going concern.

Summary

• Serina Therapeutics, Inc. reported a net loss of $4.6 million for the three months ended September 30, 2025, a significant decline from a net income of $1.4 million in the same period of 2024.
• For the nine months ended September 30, 2025, the net loss increased to $15.9 million, compared to $8.5 million for the corresponding period in 2024.
• Research and development expenses rose to $3.7 million for the quarter and $9.8 million for the nine months ended September 30, 2025, up from $2.4 million and $5.1 million respectively in 2024, driven by outsourced research, consultant spend, and clinical activities.
• The company's cash and cash equivalents stood at $8.6 million as of September 30, 2025, an increase from $3.7 million at December 31, 2024, primarily due to financing activities.
• Management has expressed substantial doubt about the company's ability to continue as a going concern, as current cash is not expected to cover anticipated operating and funding requirements for the next twelve months.
• On November 3, 2025, the FDA placed a clinical hold on the Investigational New Drug (IND) application for SER-252, the company's lead development program for advanced Parkinson's disease, requesting additional information related to a commonly used excipient.
• Serina Therapeutics completed a private placement of Series A Convertible Preferred Stock in April 2025, generating net proceeds of $4.9 million.
• The company entered into an unsecured convertible note agreement in September 2025, making up to $20 million available in tranches, with the first $5.0 million tranche drawn in September 2025.
• Material weaknesses in internal control over financial reporting were identified, stemming from insufficient qualified accounting personnel, inadequate data validation, limited segregation of duties, and reliance on manual processes.

Sentiment

Score: 2

Explanation: The sentiment is strongly negative due to the significant increase in net losses, the explicit 'going concern' warning from management, and the critical FDA clinical hold on the lead drug candidate. While capital has been raised, the underlying operational challenges and regulatory setback outweigh these financing efforts.

Positives

• Cash and cash equivalents increased significantly to $8.6 million as of September 30, 2025, from $3.7 million at December 31, 2024, bolstering short-term liquidity.
• Net cash used in operating activities for the nine months ended September 30, 2025, decreased slightly to $11.9 million from $12.5 million in the prior year, indicating a marginal improvement in operational cash burn efficiency.
• Successfully raised $4.9 million net proceeds from a private placement of Series A Convertible Preferred Stock in April 2025.
• Secured access to up to $20 million through an unsecured convertible note with a board member, with the first $5.0 million tranche already drawn.
• Generated $2.2 million net proceeds from an at-the-market (ATM) offering program, providing additional capital flexibility.
• Established a new subsidiary, Serina Therapeutics Australia Pty Ltd, in July 2025, to conduct clinical research activities in Australia, potentially expanding global R&D capabilities.

Negatives

• Reported a net loss of $4.6 million for the three months ended September 30, 2025, a reversal from a net income of $1.4 million in the same period of 2024.
• The net loss for the nine months ended September 30, 2025, significantly increased to $15.9 million, compared to $8.5 million in the prior year.
• Accumulated deficit grew to $60.2 million as of September 30, 2025, from $44.3 million at December 31, 2024, reflecting ongoing operational losses.
• Grant revenues for the three months ended September 30, 2025, were zero, down from $14 thousand in the prior year, indicating a reduction in external funding for specific projects.
• The company's cash and cash equivalents of $8.6 million are not expected to be sufficient to satisfy anticipated operating and funding requirements for the next twelve months, leading to substantial doubt about its ability to continue as a going concern.
• A clinical hold was placed by the FDA on the IND application for SER-252, the lead Parkinson's disease program, which will delay the planned SER-252-1b registrational clinical study.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to recurring losses from operations and negative cash flows.
• The company will require additional financing to fund future operations and product development, and there is no assurance that adequate financing will be available on favorable terms, if at all.
• Sales of additional equity securities, including through the ATM program or conversion of the 2025 Convertible Note, could result in significant dilution of existing stockholders' interests and cause the stock price to fall.
• The FDA regulatory approval process is lengthy, time-consuming, and inherently unpredictable, and the company may experience significant delays in clinical development and regulatory approval of its product candidates.
• The recent FDA clinical hold on the IND application for SER-252 will delay the planned registrational clinical study, impacting development timelines and increasing costs.
• The company has never generated revenue from product sales and may never become profitable, as product candidates are in early stages and require substantial further development, testing, and regulatory approval.
• Product candidates may fail at any stage of preclinical or clinical development, or reveal unfavorable characteristics such as safety concerns or lack of efficacy.
• Delays in clinical trials can arise from difficulties in patient enrollment, identifying suitable investigators, reaching agreements with trial sites or CROs, or regulatory disagreements on study design.
• Material weaknesses in internal control over financial reporting exist, including insufficient qualified accounting personnel, inadequate data validation, limited segregation of duties, and reliance on manual processes, which could lead to material misstatements.
• The company is subject to risks and uncertainties common to early-stage biotechnology companies, including technical risks, competition, dependence on key personnel, protection of proprietary technology, and compliance with government regulations.

Future Outlook

The company expects to incur substantial expenditures for the development of its product candidates and will require additional financing. It anticipates continued net losses and increasing research and development, general and administrative expenses, and capital expenditures as it advances SER-252 into Phase I clinical trials, develops other product candidates, and expands its pipeline. The successful development and commercialization of product candidates are highly uncertain, and the company does not expect to generate product sales for several years, if ever. The recent FDA clinical hold on SER-252 will impact the timeline for its lead program.

Management Comments

• "Management believes that its cash and cash equivalents of $8.6 million as of September 30, 2025, are not expected to be sufficient to satisfy the Companys anticipated operating and other funding requirements for the twelve months from the issuance of these condensed consolidated interim financial statements."
• "As such, there is substantial doubt about the Companys ability to continue as a going concern."
• "The Company plans to engage with the FDA in order to lift the clinical hold and commence with the planned SER-252-1b registrational clinical study."
• "We expect to incur substantial expenditures in the foreseeable future for the development of our product candidates and will require additional financing to continue this development."
• "We expect our research and development expenses to increase substantially for the foreseeable future as we continue to invest in research and development activities related to developing our product candidates, including investments in conducting clinical trials, manufacturing and otherwise advancing our programs."

Industry Context

Serina Therapeutics operates in the highly capital-intensive and regulated clinical-stage biotechnology industry, focusing on neurological diseases. The company's proprietary POZ drug delivery technology aims to differentiate its product candidates by improving the efficacy and safety profiles of existing and novel drugs. The industry is characterized by lengthy and uncertain regulatory approval processes, high R&D costs, and a significant reliance on external financing. The FDA clinical hold on SER-252 highlights the inherent regulatory risks and potential for delays common in drug development, particularly for advanced-stage programs like those targeting Parkinson's disease.

Comparison to Industry Standards

• The company's accumulated deficit of over $60 million and recurring net losses are typical for early-stage biotechnology companies that have not yet commercialized products.
• The reliance on equity offerings, debt financings, and collaborations for funding is standard practice in the biotech sector, where R&D costs are substantial and product revenues are distant.
• The FDA clinical hold on SER-252 is a common, albeit serious, setback in pharmaceutical development, reflecting the rigorous scrutiny and unpredictable nature of regulatory pathways for novel drug candidates.
• The company's POZ drug delivery technology, designed to improve drug profiles, positions it within a competitive landscape of drug delivery innovators, though specific comparable projects or companies are not detailed in the filing.

Corporate Governance

Legal Proceedings

• The company is not currently a party to any material legal proceedings.

Related Party Transactions

• The company sold UniverXome to Juvenescence in December 2024, with Juvenescence assuming approximately $11.3 million of secured debt.
• In April 2025, the company entered into a securities purchase agreement with related parties for a private placement of Series A Convertible Preferred Stock, generating net proceeds of $4.9 million.
• On September 9, 2025, the company entered into an unsecured convertible note (2025 Convertible Note) with Gregory Bailey, a member of the company's Board of Directors, making available up to $20 million. The first tranche of $5.0 million was drawn in September 2025.
• The 2025 Convertible Note includes Contingent Warrants for the purchase of common stock, with the warrant related to the first tranche reclassified to equity upon drawdown.
• Juvenescence exercised Post-Merger Warrants to purchase 377,865 shares of common stock for $5.0 million on June 6, 2024.
• In November 2024, the company agreed with Juvenescence to issue 1,000,000 shares of common stock for $10.0 million (in two tranches) and Juvenescence surrendered 755,728 Post-Merger Warrants, receiving Replacement Incentive Warrants.

Stakeholder Impact

• **Shareholders:** Face significant dilution risk from future equity raises and potential decline in stock price due to the clinical hold and going concern warning. The value of their investment is at substantial risk.
• **Employees:** The company's financial instability and need for additional capital could impact job security and future growth opportunities.
• **Creditors:** The 'going concern' doubt and high accumulated deficit increase the risk for current and future creditors, potentially affecting the company's ability to secure debt on favorable terms.
• **Patients/Medical Community:** The clinical hold on SER-252 delays a potential treatment for advanced Parkinson's disease, impacting patients awaiting new therapeutic options.
• **Regulatory Authorities (FDA):** The company's engagement with the FDA to address the clinical hold is critical for its lead program's progression, demonstrating compliance and responsiveness to regulatory feedback.

Next Steps

• Engage with the FDA to provide requested information and lift the clinical hold on the SER-252 IND application.
• Commence with the planned SER-252-1b registrational clinical study once the clinical hold is lifted.
• Continue to advance other product candidates through preclinical and clinical development.
• Implement remediation measures to address identified material weaknesses in internal control over financial reporting.
• Seek additional financing through equity offerings, debt financings, or collaborations to fund operations beyond the next twelve months.

Key Dates

Recommendation

The filing presents a highly concerning outlook for Serina Therapeutics. The explicit 'substantial doubt about the company's ability to continue as a going concern' is a severe warning sign for investors. This is compounded by a significant increase in net losses, indicating a high cash burn rate, and critically, an FDA clinical hold on SER-252, the company's lead development program. This clinical hold introduces significant delays and uncertainty for the company's most promising asset. While the company has recently raised capital, these funds are deemed insufficient for the next 12 months, necessitating further dilutive financing. The combination of severe liquidity issues, worsening financial performance, a major regulatory setback, and material weaknesses in internal controls points to a highly precarious situation. A seasoned investor would view these factors as overwhelmingly negative, suggesting a strong sell recommendation to mitigate further potential losses.

Keywords

Serina Therapeutics, SER-252, Parkinson's disease, clinical hold, biotechnology, drug development, POZ technology, SEC filing, 10-Q, going concern, liquidity, convertible note, ATM offering, R&D expenses, net loss, FDA, neurological diseases